Hemostatic efficacy of dipyridamole, tranexamic acid, and aprotinin in coronary bypass grafting

Ann Thorac Surg. 1995 Feb;59(2):438-42. doi: 10.1016/0003-4975(94)00865-5.

Abstract

Sixty patients (four groups of 15 patients) were entered in a randomized, controlled study to compare the efficacy of prophylactic treatment with dipyridamole, tranexamic acid, and aprotinin to reduce bleeding after elective coronary artery bypass grafting. Only patients with a preoperative platelet count of less than 246 x 10(9)/L were selected because a previous study showed that these individuals are at risk for increased postoperative bleeding. Compared to control subjects, postoperative blood loss 6 hours after operation was significantly reduced by tranexamic acid (674 +/- 411 versus 352 +/- 150 mL; p < 0.05) and by aprotinin (270 +/- 174 mL; p < 0.01). Dipyridamole did not reduce postoperative blood loss and was associated with complications in 3 patients. We conclude that hemostasis after cardiac operations can be improved with tranexamic acid and aprotinin. Dipyridamole appeared to be ineffective.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Aprotinin / adverse effects
  • Aprotinin / therapeutic use*
  • Blood Loss, Surgical / prevention & control
  • Coronary Artery Bypass*
  • Dipyridamole / adverse effects
  • Dipyridamole / therapeutic use*
  • Female
  • Hemoglobins / analysis
  • Hemostasis / drug effects*
  • Humans
  • Male
  • Middle Aged
  • Platelet Count
  • Tranexamic Acid / adverse effects
  • Tranexamic Acid / therapeutic use*

Substances

  • Hemoglobins
  • Dipyridamole
  • Tranexamic Acid
  • Aprotinin